OP Asset Management Ltd Takes Position in Edwards Lifesciences Corporation $EW

OP Asset Management Ltd purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 1st quarter, Holdings Channel.com reports. The institutional investor purchased 137,471 shares of the medical research company’s stock, valued at approximately $11,009,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $25,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter worth $25,000. MV Capital Management Inc. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $26,000. Kemnay Advisory Services Inc. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $27,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 81,038 shares of company stock worth $6,683,255 over the last ninety days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 0.1%

Edwards Lifesciences stock opened at $89.75 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock has a market capitalization of $51.68 billion, a price-to-earnings ratio of 47.74, a PEG ratio of 2.25 and a beta of 0.87. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $91.65. The business has a fifty day moving average price of $84.16 and a 200-day moving average price of $83.21.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the prior year, the company posted $0.64 EPS. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on EW shares. Barclays reissued an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. TD Cowen reiterated a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, Robert W. Baird raised their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.